ENTRY       D03068                      Drug
NAME        Belimumab (USAN);
            Belimumab (genetical recombination) (JAN);
            Benlysta (TN);
            LymphoStat-B (TN)
PRODUCT     BENLYSTA (GlaxoSmithKline LLC)
FORMULA     C6714H10428N1816O2102S52
EXACT_MASS  151791.04
MOL_WEIGHT  151884.9241
REMARK      Therapeutic category: 3999
            ATC code: L04AA26
            Product: D03068<JP/US>
EFFICACY    Immunosuppressant, Anti-BLyS antibody
  DISEASE   Systemic lupus erythematosus [DS:H00080]
  TYPE      Monoclonal antibody
TARGET      TNFSF13B (BAFF, CD257) [HSA:10673] [KO:K05476]
  PATHWAY   hsa04060(10673)  Cytokine-cytokine receptor interaction
            hsa04064(10673)  NF-kappa B signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA26 Belimumab
                  D03068  Belimumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               B lymphocyte Stimulator-specific Inhibitor
                Belimumab
                 D03068  Belimumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D03068  Belimumab (USAN); Belimumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Tumor necrosis factors
                TNFSF13B (BAFF, CD257)
                 D03068  Belimumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03068
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03068
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03068
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03068
DBLINKS     CAS: 356547-88-1
            PubChem: 17397223
            NIKKAJI: J2.313.545K
///
